| Detailed information |
|---|
| CancerLivER ID | 2514 |
| Biomarker | FGL2, GC, FLNA, FHL1, FBN2, TLN1 |
| Biomarker Name/Symbol (given in Publication) | FGL2, GC, FLNA, FHL1, FBN2, and TLN1 |
| Biomolecule | Protein |
| Subject | Human |
| Degree of Validity | Potential diagnostic marker for HCC and upregulated in HCC than non-tumor (with > 3 fold change); but not validated on independent dataset |
| Experimental Condition | HCC v/s non-tumor |
| Cancer type | Hepatocellular carcinoma |
| Regulation | Upregulated in HCC than non-tumor (with > 3 fold change) |
| Level of significance | p < 0.05 |
| Source | Tissue |
| PMID | 18715028 |
| Type of Biomarker | Diagnostic |
| Pathway | Innate Immune System, Amino acid metabolism |
| Cohort | 56 HCC: 13 metastatic tissues along with 46 poor to well differentiated hepatocellular carcinoma from patients in the age group of 40 to 72 years and 59 noncancer tissues; The tissue microarrays from Creative Biolabs consisted of 15 well differentiated, 29 moderately differentiated, and 12 poorly di |
| Sensitivity | NA |
| Specificity | NA |
| Accuracy | NA |
| AUC | NA |
| Disease | HCC v/s non-tumor |
| Year of Publication | 2008 |
| Clinical trial | NO |
| Clinical trial (NCT Number) | NA |